Boehringer Ingelheim. Boehringer Inghelheim (BI) is investing EUR 170 million ($229 million) in its chemical-production facilities in Petersburg,
Virginia, and Fornovo, Italy. The company also is doubling capacity for "Respimat" (dabigatran) at its facility in Dortmouth,
Germany. The expansion is scheduled to be completed in 2009. In 2006, BI invested EUR 50 million ($68 million) for a new pharmaceutical
R&D facility in Biberach, Germany. BI is investing more than EUR 50 million to expand its Cleveland, Ohio, facility. The expansion
will include new laboratories and office buildings. In addition, the company is expanding its LogiPack Center packaging facility
in Ingelheim, Germany.
Bayer Schering Pharma. Bayer Schering Pharma AG, formed from the Bayer Group's acquisition of Schering AG, is proceeding with an integration plan
that will result in annual savings of EUR 700 million ($951 million) from 2009. Bayer announced in 2006 that the integration
of the two companies will result in 6100 job cuts.
Schering-Plough. As part of a global manufacturing streamlining effort, Schering-Plough phased out and closed its pharmaceutical manufacturing
facility in Manati, Puerto Rico, at the end of 2006 and reduced the workforce in facilities in Las Piedras, Puerto Rico, and
Kenilworth, New Jersey. About 1000 employees were eliminated. Also, Schering-Plough invested $38 million in its pharmaceutical-sciences
center in Kenilworth and plans to invest an additional $260 million during the next three years.
1. Holding Pattern: A Special Report on the World's Top 50 Pharma Companies," Pharm. Executive
27 (5), 98–110 (2007).